Symbols / ATOS $5.95 +3.12% Atossa Therapeutics, Inc.
ATOS Chart
About
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Fundamentals
Scroll to Statements| Market Cap | 51.24M | Enterprise Value | 8.39M | Income | -34.77M | Sales | — | Book/sh | 4.57 | Cash/sh | 4.80 |
| Dividend Yield | — | Payout | 0.00% | Employees | 16 | IPO | — | P/E | — | Forward P/E | -2.38 |
| PEG | — | P/S | — | P/B | 1.30 | P/C | — | EV/EBITDA | -0.23 | EV/Sales | — |
| Quick Ratio | 5.00 | Current Ratio | 5.53 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -4.04 | EPS next Y | -2.50 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2026-03-25 | ROA | -37.43% | ROE | -62.74% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 8.61M | Shs Float | 8.61M | Short Float | 3.81% |
| Short Ratio | 3.84 | Short Interest | — | 52W High | 19.35 | 52W Low | 3.76 | Beta | 1.34 | Avg Volume | 123.64K |
| Volume | 39.33K | Target Price | $23.00 | Recom | Strong_buy | Prev Close | $5.77 | Price | $5.95 | Change | 3.12% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$23.00
Mean price target
2. Current target
$5.95
Latest analyst target
3. DCF / Fair value
$-38.11
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.95
Low
$20.00
High
$25.00
Mean
$23.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-10 | main | Ascendiant Capital | Buy → Buy | $24 |
| 2026-03-26 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-12-08 | main | Ascendiant Capital | Buy → Buy | $8 |
| 2025-09-22 | main | Ascendiant Capital | Buy → Buy | $8 |
| 2025-06-06 | main | Ascendiant Capital | Buy → Buy | $8 |
| 2025-06-05 | init | Craig-Hallum | — → Buy | $4 |
| 2025-04-21 | main | Ascendiant Capital | Buy → Buy | $7 |
| 2025-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-03-12 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-01-30 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-12-13 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-12-12 | reit | HC Wainwright & Co. | Buy → Buy | — |
| 2024-12-09 | main | Ascendiant Capital | Buy → Buy | $7 |
| 2024-11-13 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-05 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-10-31 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-09-11 | main | Ascendiant Capital | Buy → Buy | $7 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-06-28 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-06-20 | reit | Cantor Fitzgerald | — → Overweight | — |
- Atossa (ATOS) Stock: What Is Driving the Price | Q4 2025: Below Expectations - Community Trade Ideas - UBND thành phố Hải Phòng Wed, 22 Apr 2026 19
- ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill Fri, 17 Apr 2026 07
- Earnings call transcript: Atos SE Q1 2026 sees stock dip amid transformation - Investing.com ue, 21 Apr 2026 08
- Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook - PR Newswire Wed, 11 Feb 2026 08
- Atos Stock Forecast 2026–2030 | Future Outlook - Capital.com ue, 27 Jan 2026 08
- ATOS Stock Tumbles 32% — Here’s What Retail Investors Think Of The Reverse Stock Split - Stocktwits Mon, 02 Feb 2026 08
- Has Atos Rebound and Turnaround Strategy in 2025 Created a Fresh Opportunity? - Yahoo Finance Fri, 12 Dec 2025 08
- [8-K] ATOSSA THERAPEUTICS, INC. Reports Material Event - Stock Titan Mon, 26 Jan 2026 08
- ATOS Ownership | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill Fri, 17 Apr 2026 07
- Atos Stock Forecast | Bull Division Sale Completed - Capital.com Wed, 08 Apr 2026 07
- Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - PR Newswire Wed, 25 Mar 2026 07
- Atos (ENXTPA:ATO): Examining the Stock’s Valuation After a Strong Recent Rally - Yahoo Finance Mon, 20 Oct 2025 07
- Atossa (NASDAQ: ATOS) CEO Steven Quay granted 65,000 RSUs after reverse split - Stock Titan ue, 31 Mar 2026 07
- Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program - PR Newswire hu, 05 Feb 2026 08
- Assessing Atos (ENXTPA:ATO) Valuation After Recent Share Price Weakness - Yahoo Finance Wed, 18 Feb 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
37.14
+34.47%
|
27.62
-11.97%
|
31.38
+13.31%
|
27.69
|
| Research And Development |
|
21.18
+50.07%
|
14.12
-18.56%
|
17.33
+14.92%
|
15.08
|
| Selling General And Administration |
|
15.96
+18.16%
|
13.50
-3.84%
|
14.04
+11.38%
|
12.61
|
| General And Administrative Expense |
|
15.96
+18.16%
|
13.50
-3.84%
|
14.04
+11.38%
|
12.61
|
| Other Gand A |
|
15.96
+18.16%
|
13.50
-3.84%
|
14.04
+11.38%
|
12.61
|
| Total Expenses |
|
37.14
+34.47%
|
27.62
-11.97%
|
31.38
+13.31%
|
27.69
|
| Operating Income |
|
-37.14
-34.47%
|
-27.62
+11.97%
|
-31.38
-13.31%
|
-27.69
|
| Total Operating Income As Reported |
|
-37.14
-34.47%
|
-27.62
+11.97%
|
-31.38
-13.31%
|
-27.69
|
| EBITDA |
|
-37.12
-34.49%
|
-27.60
+11.96%
|
-31.35
-13.26%
|
-27.68
|
| Normalized EBITDA |
|
-37.12
-43.37%
|
-25.89
+8.71%
|
-28.36
-2.46%
|
-27.68
|
| Reconciled Depreciation |
|
0.02
-5.88%
|
0.02
-26.09%
|
0.02
+187.50%
|
0.01
|
| EBIT |
|
-37.14
-34.47%
|
-27.62
+11.97%
|
-31.38
-13.31%
|
-27.69
|
| Total Unusual Items |
|
0.00
+100.00%
|
-1.71
+42.81%
|
-2.99
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.00
+100.00%
|
-1.71
+42.81%
|
-2.99
|
0.00
|
| Special Income Charges |
|
0.00
+100.00%
|
-1.71
+42.81%
|
-2.99
|
0.00
|
| Write Off |
|
0.00
-100.00%
|
1.71
-42.81%
|
2.99
|
0.00
|
| Net Income |
|
-34.77
-36.33%
|
-25.50
+15.25%
|
-30.09
-11.62%
|
-26.96
|
| Pretax Income |
|
-34.77
-36.33%
|
-25.50
+15.25%
|
-30.09
-11.62%
|
-26.96
|
| Net Non Operating Interest Income Expense |
|
2.38
-41.31%
|
4.05
-6.75%
|
4.34
+395.21%
|
0.88
|
| Net Interest Income |
|
2.38
-41.31%
|
4.05
-6.75%
|
4.34
+395.21%
|
0.88
|
| Interest Income Non Operating |
|
2.38
-41.31%
|
4.05
-6.75%
|
4.34
+395.21%
|
0.88
|
| Interest Income |
|
2.38
-41.31%
|
4.05
-6.75%
|
4.34
+395.21%
|
0.88
|
| Other Income Expense |
|
-0.01
+99.69%
|
-1.93
+36.83%
|
-3.06
-1995.89%
|
-0.15
|
| Other Non Operating Income Expenses |
|
-0.01
+97.31%
|
-0.22
-218.57%
|
-0.07
+52.05%
|
-0.15
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-34.77
-36.33%
|
-25.50
+15.25%
|
-30.09
-11.62%
|
-26.96
|
| Net Income From Continuing Operation Net Minority Interest |
|
-34.77
-36.33%
|
-25.50
+15.25%
|
-30.09
-11.62%
|
-26.96
|
| Net Income From Continuing And Discontinued Operation |
|
-34.77
-36.33%
|
-25.50
+15.25%
|
-30.09
-11.62%
|
-26.96
|
| Net Income Continuous Operations |
|
-34.77
-36.33%
|
-25.50
+15.25%
|
-30.09
-11.62%
|
-26.96
|
| Normalized Income |
|
-34.77
-46.13%
|
-23.79
+12.21%
|
-27.10
-0.53%
|
-26.96
|
| Net Income Common Stockholders |
|
-34.77
-36.33%
|
-25.50
+15.25%
|
-30.09
-11.62%
|
-26.96
|
| Diluted EPS |
|
-4.04
-32.89%
|
-3.04
+15.56%
|
-3.60
-14.29%
|
-3.15
|
| Basic EPS |
|
-4.04
-32.89%
|
-3.04
+15.56%
|
-3.60
-14.29%
|
-3.15
|
| Basic Average Shares |
|
8.61
+2.63%
|
8.39
-0.18%
|
8.41
-0.43%
|
8.44
|
| Diluted Average Shares |
|
8.61
+2.63%
|
8.39
-0.18%
|
8.41
-0.43%
|
8.44
|
| Diluted NI Availto Com Stockholders |
|
-34.77
-36.33%
|
-25.50
+15.25%
|
-30.09
-11.62%
|
-26.96
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Total Assets |
|
47.61
-37.72%
|
76.44
-20.58%
|
96.25
|
| Current Assets |
|
45.62
-38.73%
|
74.46
-19.26%
|
92.22
|
| Cash Cash Equivalents And Short Term Investments |
|
41.30
-41.90%
|
71.08
-19.64%
|
88.46
|
| Cash And Cash Equivalents |
|
41.30
-41.90%
|
71.08
-19.64%
|
88.46
|
| Receivables |
|
—
|
—
|
0.00
|
| Taxes Receivable |
|
—
|
—
|
0.00
|
| Prepaid Assets |
|
4.08
+29.64%
|
3.14
-12.35%
|
3.59
|
| Restricted Cash |
|
0.11
+0.00%
|
0.11
+0.00%
|
0.11
|
| Other Current Assets |
|
0.13
+11.76%
|
0.12
+91.94%
|
0.06
|
| Total Non Current Assets |
|
1.99
+0.15%
|
1.99
-50.73%
|
4.03
|
| Net PPE |
|
—
|
—
|
—
|
| Gross PPE |
|
—
|
—
|
—
|
| Accumulated Depreciation |
|
—
|
—
|
—
|
| Machinery Furniture Equipment |
|
—
|
—
|
—
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
—
|
| Investments And Advances |
|
—
|
0.00
-100.00%
|
1.71
|
| Long Term Equity Investment |
|
—
|
—
|
—
|
| Other Non Current Assets |
|
1.99
+0.15%
|
1.99
-14.46%
|
2.32
|
| Total Liabilities Net Minority Interest |
|
8.26
+66.20%
|
4.97
-5.14%
|
5.24
|
| Current Liabilities |
|
8.26
+66.20%
|
4.97
-5.14%
|
5.24
|
| Payables And Accrued Expenses |
|
6.26
+224.78%
|
1.93
-6.50%
|
2.06
|
| Payables |
|
4.29
+532.25%
|
0.68
-15.76%
|
0.81
|
| Accounts Payable |
|
4.29
+532.25%
|
0.68
-15.76%
|
0.81
|
| Current Accrued Expenses |
|
1.97
+57.76%
|
1.25
-0.56%
|
1.26
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.89
-41.67%
|
1.53
+11.75%
|
1.37
|
| Current Capital Lease Obligation |
|
—
|
—
|
—
|
| Other Current Liabilities |
|
1.10
-27.21%
|
1.51
-16.42%
|
1.80
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
39.35
-44.94%
|
71.48
-21.47%
|
91.02
|
| Common Stock Equity |
|
39.35
-44.94%
|
71.48
-21.47%
|
91.02
|
| Capital Stock |
|
1.55
+0.00%
|
1.55
-93.20%
|
22.79
|
| Common Stock |
|
1.55
+0.00%
|
1.55
-93.20%
|
22.79
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
8.70
+0.00%
|
8.70
+3.05%
|
8.44
|
| Ordinary Shares Number |
|
8.61
+0.00%
|
8.61
+3.09%
|
8.35
|
| Treasury Shares Number |
|
0.09
+0.00%
|
0.09
+0.00%
|
0.09
|
| Additional Paid In Capital |
|
285.84
+0.93%
|
283.19
+10.63%
|
255.99
|
| Retained Earnings |
|
-246.56
-16.42%
|
-211.79
-13.69%
|
-186.29
|
| Treasury Stock |
|
1.48
+0.00%
|
1.48
+0.00%
|
1.48
|
| Total Equity Gross Minority Interest |
|
39.35
-44.94%
|
71.48
-21.47%
|
91.02
|
| Total Capitalization |
|
39.35
-44.94%
|
71.48
-21.47%
|
91.02
|
| Working Capital |
|
37.36
-46.23%
|
69.49
-20.11%
|
86.98
|
| Invested Capital |
|
39.35
-44.94%
|
71.48
-21.47%
|
91.02
|
| Total Debt |
|
—
|
—
|
—
|
| Capital Lease Obligations |
|
—
|
—
|
—
|
| Net Tangible Assets |
|
39.35
-44.94%
|
71.48
-21.47%
|
91.02
|
| Tangible Book Value |
|
39.35
-44.94%
|
71.48
-21.47%
|
91.02
|
| Available For Sale Securities |
|
—
|
—
|
1.71
|
| Investmentin Financial Assets |
|
—
|
0.00
-100.00%
|
1.71
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-29.76
-41.52%
|
-21.03
-0.43%
|
-20.94
-0.87%
|
-20.76
|
| Cash Flow From Continuing Operating Activities |
|
-29.76
-41.52%
|
-21.03
-0.43%
|
-20.94
-0.87%
|
-20.76
|
| Net Income From Continuing Operations |
|
-34.77
-36.33%
|
-25.50
+15.25%
|
-30.09
-11.62%
|
-26.96
|
| Depreciation Amortization Depletion |
|
0.02
-5.88%
|
0.02
-26.09%
|
0.02
+187.50%
|
0.01
|
| Depreciation |
|
0.02
-5.88%
|
0.02
-26.09%
|
0.02
|
—
|
| Depreciation And Amortization |
|
0.02
-5.88%
|
0.02
-26.09%
|
0.02
+187.50%
|
0.01
|
| Stock Based Compensation |
|
2.65
+15.45%
|
2.29
-50.40%
|
4.62
-31.92%
|
6.79
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
1.71
-42.81%
|
2.99
|
0.00
|
| Operating Gains Losses |
|
—
|
0.01
|
—
|
0.00
|
| Change In Working Capital |
|
2.35
+423.66%
|
0.45
-70.51%
|
1.52
+353.59%
|
-0.60
|
| Change In Receivables |
|
—
|
—
|
0.74
+125.84%
|
0.33
|
| Change In Prepaid Assets |
|
-0.95
-345.08%
|
0.39
-89.12%
|
3.55
+227.95%
|
-2.77
|
| Change In Payables And Accrued Expense |
|
4.00
+2311.05%
|
-0.18
+91.94%
|
-2.25
-206.75%
|
2.10
|
| Change In Accrued Expense |
|
0.39
+818.52%
|
-0.05
+37.21%
|
-0.09
-110.06%
|
0.85
|
| Change In Payable |
|
3.61
+2945.67%
|
-0.13
+94.12%
|
-2.16
-273.00%
|
1.25
|
| Change In Account Payable |
|
3.61
+2945.67%
|
-0.13
+94.12%
|
-2.16
-273.00%
|
1.25
|
| Change In Other Working Capital |
|
-0.30
-246.15%
|
0.21
+61.24%
|
0.13
-62.17%
|
0.34
|
| Change In Other Current Assets |
|
0.00
-98.79%
|
0.33
+119.51%
|
-1.70
-184.25%
|
-0.60
|
| Change In Other Current Liabilities |
|
-0.41
-38.51%
|
-0.30
-116.59%
|
1.78
+89300.00%
|
-0.00
|
| Investing Cash Flow |
|
-0.02
-21.05%
|
-0.02
-35.71%
|
-0.01
+99.70%
|
-4.73
|
| Cash Flow From Continuing Investing Activities |
|
-0.02
-21.05%
|
-0.02
-35.71%
|
-0.01
+99.70%
|
-4.73
|
| Net PPE Purchase And Sale |
|
-0.02
-21.05%
|
-0.02
-35.71%
|
-0.01
+48.15%
|
-0.03
|
| Purchase Of PPE |
|
-0.02
-21.05%
|
-0.02
-35.71%
|
-0.01
+48.15%
|
-0.03
|
| Capital Expenditure |
|
-0.02
-21.05%
|
-0.02
-35.71%
|
-0.01
+48.15%
|
-0.03
|
| Net Investment Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-4.70
|
| Purchase Of Investment |
|
—
|
—
|
0.00
+100.00%
|
-4.70
|
| Financing Cash Flow |
|
0.00
-100.00%
|
3.67
+349.02%
|
-1.48
|
0.00
|
| Cash Flow From Continuing Financing Activities |
|
0.00
-100.00%
|
3.67
+349.02%
|
-1.48
|
0.00
|
| Net Common Stock Issuance |
|
—
|
0.00
+100.00%
|
-1.48
|
0.00
|
| Common Stock Payments |
|
—
|
0.00
+100.00%
|
-1.48
|
0.00
|
| Repurchase Of Capital Stock |
|
—
|
0.00
+100.00%
|
-1.48
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
3.67
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
-29.79
-71.41%
|
-17.38
+22.53%
|
-22.43
+11.99%
|
-25.49
|
| Beginning Cash Position |
|
71.19
-19.62%
|
88.57
-20.21%
|
111.00
-18.67%
|
136.49
|
| End Cash Position |
|
41.41
-41.84%
|
71.19
-19.62%
|
88.57
-20.21%
|
111.00
|
| Free Cash Flow |
|
-29.79
-41.50%
|
-21.05
-0.45%
|
-20.95
-0.81%
|
-20.79
|
| Common Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Capital Stock |
|
—
|
—
|
—
|
0.00
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-16 View
- 42026-03-31 View
- 42026-03-30 View
- 10-K2026-03-25 View
- 8-K2026-03-25 View
- 8-K2026-02-20 View
- 8-K2026-02-17 View
- 8-K2026-02-11 View
- 8-K2026-01-26 View
- 42026-01-22 View
- 8-K2026-01-09 View
- 8-K2026-01-06 View
- 8-K2025-12-04 View
- 10-Q2025-11-12 View
- 8-K2025-11-12 View
- 42025-10-21 View
- 8-K2025-10-14 View
- 8-K2025-09-26 View
- 8-K2025-09-08 View
- 8-K2025-08-21 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|